Analytical Data
-
Gene name
PTPRC/CD45RABC
- Application
-
Alternative Names
L-CA; CD45; T200; PTPRC; B220; CD45R; GP180; LCA; LY5; EC 3.1.3.48
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P08575-3
-
Expression Region
Q26-L577
-
Molecular Weight
120-130 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PTPRC, also known as CD45, is a key receptor-like protein tyrosine phosphatase that plays a crucial role in the regulation of immune cell signaling. It is predominantly expressed on the surface of leukocytes, including T cells and B cells, where it modulates various cellular processes such as activation, proliferation, and differentiation. The full-length CD45 protein exists in multiple isoforms generated by alternative splicing, with CD45RA, CD45RB, and CD45RABC being significant in defining T cell subsets. Research on PTPRC/CD45RABC recombinant proteins has gained traction due to their potential therapeutic implications in autoimmune diseases, cancer immunotherapy, and transplant rejection. By studying these proteins, scientists aim to elucidate the molecular mechanisms underlying CD45-mediated signaling pathways, which is critical for understanding T cell responses and the overall immune system function. Furthermore, recombinant forms allow for detailed structural and functional analyses, facilitating the design of targeted therapies to modulate immune responses effectively. This ongoing research is vital for developing novel strategies to enhance immune tolerance or boost immune response, depending on the clinical context. Overall, the investigation of PTPRC/CD45RABC recombinant proteins holds promise for advancing our knowledge of immunology and improving treatment approaches for various diseases.
